Maxpro Capital Acquisition (JMAC) Competitors $3.93 -0.25 (-6.05%) As of 08/29/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock JMAC vs. LRMR, CADL, ALT, AMRN, DSGN, ACB, DMAC, OCGN, DRUG, and GLUEShould you be buying Maxpro Capital Acquisition stock or one of its competitors? The main competitors of Maxpro Capital Acquisition include Larimar Therapeutics (LRMR), Candel Therapeutics (CADL), Altimmune (ALT), Amarin (AMRN), Design Therapeutics (DSGN), Aurora Cannabis (ACB), DiaMedica Therapeutics (DMAC), Ocugen (OCGN), Bright Minds Biosciences (DRUG), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry. Maxpro Capital Acquisition vs. Its Competitors Larimar Therapeutics Candel Therapeutics Altimmune Amarin Design Therapeutics Aurora Cannabis DiaMedica Therapeutics Ocugen Bright Minds Biosciences Monte Rosa Therapeutics Maxpro Capital Acquisition (NASDAQ:JMAC) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends. Is JMAC or LRMR more profitable? Maxpro Capital Acquisition's return on equity of 0.00% beat Larimar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Maxpro Capital AcquisitionN/A N/A N/A Larimar Therapeutics N/A -62.92%-53.98% Which has more risk & volatility, JMAC or LRMR? Maxpro Capital Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Do analysts recommend JMAC or LRMR? Larimar Therapeutics has a consensus target price of $18.43, indicating a potential upside of 409.08%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Larimar Therapeutics is more favorable than Maxpro Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 Does the media favor JMAC or LRMR? In the previous week, Maxpro Capital Acquisition and Maxpro Capital Acquisition both had 1 articles in the media. Larimar Therapeutics' average media sentiment score of 0.94 beat Maxpro Capital Acquisition's score of 0.00 indicating that Larimar Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Maxpro Capital Acquisition Neutral Larimar Therapeutics Positive Do institutionals & insiders believe in JMAC or LRMR? 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Comparatively, 4.5% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has higher valuation and earnings, JMAC or LRMR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaxpro Capital AcquisitionN/AN/AN/AN/AN/ALarimar TherapeuticsN/AN/A-$80.60M-$1.56-2.32 SummaryLarimar Therapeutics beats Maxpro Capital Acquisition on 7 of the 10 factors compared between the two stocks. Get Maxpro Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JMAC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JMAC vs. The Competition Export to ExcelMetricMaxpro Capital AcquisitionHolding Offices IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$52.80M$225.03M$2.54B$9.84BDividend YieldN/A3.17%2.54%4.04%P/E RatioN/A0.1726.4726.61Price / SalesN/A544.96238.97176.28Price / CashN/A123.7023.5759.65Price / BookN/A8.7333.486.59Net IncomeN/A-$11.59M$26.72M$266.12M7 Day Performance-34.96%-2.81%0.45%0.17%1 Month Performance-35.97%2.80%2.41%3.02%1 Year Performance3,173.69%141.36%25.86%19.69% Maxpro Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JMACMaxpro Capital AcquisitionN/A$3.93-6.1%N/A+3,177.2%$52.80MN/A0.002,021News CoverageLRMRLarimar Therapeutics2.1806 of 5 stars$3.99+2.2%$18.43+362.4%-55.0%$329.05MN/A-2.5530CADLCandel Therapeutics2.4364 of 5 stars$5.89-0.3%$22.00+273.5%-9.2%$323.91M$120K-8.5560News CoveragePositive NewsALTAltimmune3.2658 of 5 stars$3.67-0.1%$17.40+374.8%-42.1%$323.47M$20K-3.1150AMRNAmarin0.242 of 5 stars$15.50+0.2%$12.00-22.6%+24.1%$320.90M$228.61M-4.22360News CoveragePositive NewsDSGNDesign Therapeutics0.263 of 5 stars$5.60+5.9%N/A+17.4%$318.12MN/A-4.9940ACBAurora Cannabis0.593 of 5 stars$5.65+5.9%N/A-9.8%$316.97M$246.72M-29.551,130DMACDiaMedica Therapeutics1.4498 of 5 stars$6.01+0.4%$12.33+105.4%+44.9%$310.40MN/A-8.7020OCGNOcugen1.4175 of 5 stars$1.06+1.4%$6.00+468.7%-19.7%$308.38M$4.05M-5.2780DRUGBright Minds Biosciences2.4182 of 5 stars$43.02-0.8%$83.25+93.5%+3,638.5%$302.86MN/A-46.26N/APositive NewsGLUEMonte Rosa Therapeutics2.7356 of 5 stars$4.82+3.1%$15.33+218.4%-24.9%$297.37M$75.62M13.3890Positive News Related Companies and Tools Related Companies LRMR Competitors CADL Competitors ALT Competitors AMRN Competitors DSGN Competitors ACB Competitors DMAC Competitors OCGN Competitors DRUG Competitors GLUE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JMAC) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maxpro Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maxpro Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JMAC Stock Alerts